Adrian Wong1,2, Afrah Alkazemi2, I Mary Eche2, Camille R Petri3, Todd Sarge4, Michael N Cocchi4,5. 1. Department of Pharmacy Practice, 1825MCPHS University, Boston, MA, USA. 2. Department of Pharmacy, 1859Beth Israel Deaconess Medical Center, Boston, MA, USA. 3. Division of Pulmonary, Critical Care and Sleep Medicine, 1859Beth Israel Deaconess Medical Center, Boston, MA, USA. 4. Department of Anesthesia, Critical Care and Pain Medicine, 1859Beth Israel Deaconess Medical Center, Boston, MA, USA. 5. Department of Emergency Medicine, 1859Beth Israel Deaconess Medical Center, Boston, MA, USA.
Abstract
PURPOSE: Catecholamines are first-line vasopressors for hemodynamic support in distributive shock but are associated with adverse effects, which may be mitigated with noncatecholamine vasopressors. Angiotensin II (ATII) is a noncatecholamine vasopressor recently approved for the management of distributive shock, but limited data support its clinical utility. The purpose of this study was to describe our institution's usage of ATII including patient outcomes (eg, response to therapy, safety profile). MATERIALS AND METHODS: Patients who received ATII at our institution were included. Patient demographics, degree of concordance with institutional ATII use guidelines, safety profile of ATII, and response to therapy (1 and 3 hours after ATII initiation) were collected. RESULTS: A total of 16 patients received ATII for distributive shock. The median Sequential Organ Failure Assessment score at the time of ATII initiation was 16.5 (interquartile range: 15.8-20.0). Fourteen (87.5%) patients met institutional guidelines for ATII use; 10 (62.5%) and 8 (50.0%) patients met our definition for response at 1 and 3 hours, respectively. No patients developed thrombotic or infectious complications after receiving ATII. CONCLUSIONS: In this cohort, ATII appears to be well tolerated in patients with a high predicted mortality. Future studies evaluating the clinical efficacy of ATII are needed to determine its role in the management of distributive shock.
PURPOSE: Catecholamines are first-line vasopressors for hemodynamic support in distributive shock but are associated with adverse effects, which may be mitigated with noncatecholamine vasopressors. Angiotensin II (ATII) is a noncatecholamine vasopressor recently approved for the management of distributive shock, but limited data support its clinical utility. The purpose of this study was to describe our institution's usage of ATII including patient outcomes (eg, response to therapy, safety profile). MATERIALS AND METHODS: Patients who received ATII at our institution were included. Patient demographics, degree of concordance with institutional ATII use guidelines, safety profile of ATII, and response to therapy (1 and 3 hours after ATII initiation) were collected. RESULTS: A total of 16 patients received ATII for distributive shock. The median Sequential Organ Failure Assessment score at the time of ATII initiation was 16.5 (interquartile range: 15.8-20.0). Fourteen (87.5%) patients met institutional guidelines for ATII use; 10 (62.5%) and 8 (50.0%) patients met our definition for response at 1 and 3 hours, respectively. No patients developed thrombotic or infectious complications after receiving ATII. CONCLUSIONS: In this cohort, ATII appears to be well tolerated in patients with a high predicted mortality. Future studies evaluating the clinical efficacy of ATII are needed to determine its role in the management of distributive shock.
Authors: Susan E Smith; Andrea S Newsome; Yanglin Guo; Jason Hecht; Michael T McCurdy; Michael A Mazzeffi; Jonathan H Chow; Shravan Kethireddy Journal: J Intensive Care Med Date: 2020-11-24 Impact factor: 3.510
Authors: Priya Ramaswamy; Jen J Gong; Sameh N Saleh; Samuel A McDonald; Seth Blumberg; Richard J Medford; Xinran Liu Journal: J Am Med Inform Assoc Date: 2022-06-14 Impact factor: 7.942
Authors: Michele Quan; Nam Cho; Thomas Bushell; Joseph Mak; Nolan Nguyen; Jane Litwak; Nicholas Rockwood; H Bryant Nguyen Journal: Crit Care Explor Date: 2022-01-18
Authors: Patrick M Wieruszewski; Erica D Wittwer; Kianoush B Kashani; Daniel R Brown; Simona O Butler; Angela M Clark; Craig J Cooper; Danielle L Davison; Ognjen Gajic; Kyle J Gunnerson; Rachel Tendler; Kristin C Mara; Erin F Barreto Journal: Chest Date: 2020-08-31 Impact factor: 9.410